These findings shed light on a novel regulatory mechanism involving FGF12 and β‐Trcp that modulates the MDM2 protein level, and highlights the potential therapeutic relevance of targeting this interaction for diseases associated with MDM2 dysregulation, such as psoriasis. The gene discussed is MDM2; the disease is psoriasis.